, Volume 34, Supplement 1, pp S303–S305

n-3 fatty acids and coronary heart disease—the urgent need of clinical trials

Clinical Trials And New Products

DOI: 10.1007/BF02562325

Cite this article as:
Schmidt, E.B. & Dyerberg, J. Lipids (1999) 34: S303. doi:10.1007/BF02562325


Data from epidemiological studies, animal experiments, and clinical trials of biochemical effects in humans lend support for a beneficial role of n-3 PUFA in CHD. So far only a few trials of n-3 PUFA with clinical endpoints have been published. Further clinical studies in patients with acute myocardial ischemia, post-MI patients, patients undergoing coronary bypass surgery or stenting during PTCA, and patients with arrhythmias should be undertaken. Only results from controlled clinical trials with hard end points can establish whether n-3 PUFA reduce the risk of CHD and will have an impact on patient treatment.



coronary heart disease


myocardial infarction


percutaneous transluminal coronary angioplasty

n-3 PUFA

n-3 polyunsaturated fatty acid

Copyright information

© AOCS Press 1999

Authors and Affiliations

  1. 1.Department of MedicineHjørring/Brønderslev HospitalDenmark
  2. 2.Medi-Lab a.s.Copenhagen KDenmark